CARDIOL THERAPEUTICS INC-A (CRDL)
CA14161Y2006 - Common Stock
Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!
“Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside”
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially...
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024
CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cardiol Therapeutics (NASDAQ:CRDL) just reported results for the second quarter...
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot study topline results.
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce...
Sector Spotlight: Orphan Drug Developers With Significant Upside
Sector Spotlight: Orphan Drug Developers With Significant Upside
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record of strong recoveries, with the sector typically seeing double-digit gains after a downturn. This is something investors shouldn’t ignore.
CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024
CRDL stock results show that Cardiol Therapeutics met analyst estimates for earnings per share the first quarter of 2024.
CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cardiol Therapeutics (NASDAQ:CRDL) just reported results for the first quarter ...
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023
CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)...
Cardiol stock rallies 28% on FDA orphan drug status for CardiolRx (NASDAQ:CRDL)
Cardiol Therapeutics' (CRDL) stock surged 28% after the FDA granted orphan drug designation for CardiolRx in the treatment for pericarditis. Read more here.
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)...
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
Toronto, ON, October 13, 2013 (PlatoData via 500NewsWire) -- In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence.
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac...
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule Multi-Center,...